Hadasit, Anadis to Form Joint Venture Company

Hadasit, the technology transfer company of Israel’s Hadassah Medical Organization, and Australian biotechnology company Anadis will form a joint venture tentatively called Immuron, which will develop a line of therapeutic products for the treatment of inflammatory diseases, infectious diseases and cancers.

Preclinical studies will begin in January, and Phase I clinical trials are scheduled to start in the second half of 2009.

The preclinical through Phase II studies will be conducted at Hadasit, and Anadis will carry out the custom manufacturing of the commercial products. New intellectual property will be licensed back to Anadis for use in its research initiatives, Hadasit said.